Drug interactions between Kalydeco and Orthoclone OKT3
|Orthoclone OKT3 (muromonab-cd3)|
Interactions between your drugs
There were no interactions found in our database between Kalydeco and Orthoclone OKT3 - however, this does not necessarily mean no interactions exist. Always consult with your doctor or pharmacist.
- Orthoclone OKT3 is a member of the drug class selective immunosuppressants.
- Orthoclone OKT3 is used to treat the following conditions:
Drug and food interactions
Applies to: Kalydeco (ivacaftor)
Ivacaftor should be taken with fat-containing foods such as eggs, avocados, nuts, butter, peanut butter, cheese pizza, and whole-milk dairy products to help with its absorption. Do not consume grapefruit juice or any food that contains grapefruit or Seville oranges during treatment with ivacaftor unless directed otherwise by your doctor. Grapefruit juice can significantly increase the blood levels of ivacaftor. This may increase the risk and/or severity of serious side effects such as liver damage. Call your doctor immediately if you have fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, abdominal pain, dark urine, pale stools, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No interaction information available.|